
Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Free Report) – Research analysts at HC Wainwright issued their FY2026 earnings estimates for Basilea Pharmaceutica in a research note issued to investors on Friday, November 13th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn $8.49 per share for the year.
Basilea Pharmaceutica Price Performance
Shares of OTCMKTS:BPMUF opened at $84.00 on Tuesday. Basilea Pharmaceutica has a 12 month low of $59.29 and a 12 month high of $84.00. The company has a debt-to-equity ratio of 0.44, a quick ratio of 5.97 and a current ratio of 6.60. The company’s fifty day simple moving average is $77.28 and its 200 day simple moving average is $70.05.
About Basilea Pharmaceutica
Basilea Pharmaceutica is a Swiss biopharmaceutical company founded in 2000 and headquartered in Basel. It focuses on developing and commercializing medicines for serious bacterial and fungal infections. The company’s products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive aspergillosis and mucormycosis, and Zevtera (ceftobiprole), an antibiotic used for certain serious bacterial infections. Basilea makes its medicines available in multiple countries through a combination of its own commercial activities and partnerships.
Featured Stories
- Five stocks we like better than Basilea Pharmaceutica
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
